Amycretin Over the Counter Weight Loss Pills – Is it the New Ozempic Pill?

Photo of author

Peter Williams

Amycretin Over the Counter Weight Loss Pills

With obesity levels soaring worldwide, a lot of people are searching for something that can help them to lose weight. From standard diet pills to weight loss injections and surgical procedures, such as gastric band surgery, there are already plenty of options available and it may not be too long before there is a new diet pill that is more effective and safer than Ozempic.

Amycretin is a weight medicine that’s taken daily and used alongside diet and exercise to speed up the weight loss process. It’s a combination medication that pairs Semaglutide with an experimental drug called Cagrilintide.

During a recent investor gathering, Novo Nordisk unveiled findings from a preliminary clinical study on a novel anti-obesity medication named Amycretin. This orally administered agent has shown potential to outperform the corporation’s widely recognized weight management medication, Wegovy.

Administered once daily, Amycretin demonstrated a notable outcome in the study participants, who experienced an average weight reduction of 13% within a span of 12 weeks. This contrasts with the outcomes of Wegovy, which led to an average weight loss of about 6% during the same timeframe.

The mechanism of amycretin is particularly innovative, as it fuses the effects of two distinct therapeutic agents into a single compound. This dual-targeting molecule engages with both GLP-1 and amylin, which are hormones that play key roles in appetite regulation and glucose balance.

GLP-1 is the focus of existing therapies such as semaglutide and tirzepatide—the active ingredients in prominent drugs for diabetes and obesity like Ozempic, Wegovy, Mounjaro, and Zepbound. Novo, along with companies like Zealand Pharma, regards amylin as a promising cornerstone for the next wave of anti-obesity treatments.

In addition to the oral formulation, Novo Nordisk is exploring an injectable version of amycretin, which would be administered subcutaneously, similar to Wegovy and Zepbound. This variant of the drug is currently under investigation in an early-stage trial, with results anticipated around 2025.

Martin Holst Lange, Novo Nordisk’s Chief of Development, expressed optimism about the initial trial findings for amycretin. He indicated that these outcomes warrant further exploration and announced plans to initiate a more extensive Phase 2 study in the latter half of the year.

OTC Alternatives Available Now

Amycretin is not to dissimilar to the other injectable weight loss drugs in circulation in terms of caveats. There have been several negative aspects of Ozempic, Wegovy and Mounjaro that have pushed some natural alternatives to the forefront.

For all their efficacy, the injectable drugs do have a tendency to cause side effects, some of them quite serious and life changing. These have been well documented. There is also the high price with monthly costs reaching $1000 for some.

Non prescription oral weight loss brands such as PhenQ and Zotrim have both been on the market for over decade and work in much the same way as the injectable drugs.

PhenQ and Zotrim both suppress appetite and help to control calorie intake – this is essentially what Amycretin, Ozempic and Mounjaro do. The advantage of the oral products like PhenQ is that they not directly alter insulin production like Amycretin or Ozempic, which is a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates insulin secretion.

Advantages of PhenQ over Injectable (GLP-1)Drugs:

  1. Over-the-counter availability: PhenQ is a dietary supplement that can be purchased without a prescription, making it more accessible than injectable drugs, which requires a doctor’s prescription.
  2. Non-invasive administration: PhenQ comes in pill form, which is easier and more convenient to take.
  3. Cost: As an over-the-counter supplement, PhenQ is generally more affordable than Amycretin, Ozempic etc, which can be expensive, especially without insurance coverage.
  4. Side effects: PhenQ’s natural ingredients may have a lower risk of severe side effects compared to the injectables, which can cause gastrointestinal issues, pancreatitis, and thyroid tumors.

Amycretin Weight Loss Pill – Appetite Suppressant

Amycretin is a diet pill that’s presently being developed by Nova Nordisk, the European pharmaceutical company that created the Wegovy weight loss jab. Like Wegovy, Amycretin provides the drug semaglutide.

Semaglutide is also the key ingredient in Ozempic, which has FDA approval as a treatment for type 2 diabetes and is also often prescribed off-label for weight loss.

However, Amycretin isn’t Nova’s first oral semaglutide pill. That honor goes to Rybelsus, an FDA-approved anti-diabetic medication. Although Ozempic and Rybelsus are only approved for treating type 2 diabetics, doctors often prescribe them as off-label weight loss medicines. The FDA permits doctors in the US to use their own discretion and prescribe approved medications in roles other than the ones they are intended for.

Ozempic was the original semaglutide product. It gained FDA approval in December 2017 and doctors were quick to note weight loss was a common side effect.

Keen to exploit this, Novo began trialing a stronger version called Wegovy. It helped the overweight study participants reduce their body weight by 6% in 12 weeks. Based on the strength of this data, in June 2021, the FDA approved the use of Wegovy for chronic weight management in overweight and obese adults.

During an investors meeting that took place on March 7, 2024, Novo shared some news that quickly leaked out and became a hot topic of interest. Treatment with its new diet pill, Amycretin, helped the participants in a clinical trial to reduce their weight by 13% in 12 weeks.

This knowledge gave the company’s share value a rapid boost. Novo Nordisk is presently estimated to be worth around $566BN more than Tesla!

Ozempic pen

Although the company has yet to share the full study data, if Amycretin goes on to gain FDA approval, Novo could have another runaway success on its hands. Its two injectable semaglutide medications are so popular it sometimes struggles to keep up with the demand, resulting in shortages that are alarming to those who find the supply of their medications has stalled.

However, with greater potency than Ozempic and Wegovy and no need for weekly injections, it’s more than possible that people using semaglutide injections for weight loss may want to switch to Amycretin. This may take some of the pressure off on the production side. It may also cause Novo to experience a fierce demand for Amycretin that far exceeds anything the company has experienced so far.

Related content:
New Vibrating Pill for Weight Loss – What is the Vibes Diet Pill?

What Is Amycretin?

Amycretin is a weight medicine that’s taken daily and used alongside diet and exercise to speed up the weight loss process. It’s a combination medication that pairs Semaglutide with an experimental drug called Cagrilintide.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Cagrilintide is a dual amylin and calcitonin receptor agonist.

Drugs that function as receptor agonists bind to and activate specific receptors in the body, mimicking the neurotransmitter or hormone that would normally bind with it. Semaglutide binds with GLP-1 receptors. Cagrilintide binds the receptors for Amylin—a pancreas hormone.

Due to its dual nature, Amycretin can suppress appetite in a similar way to Ozempic and Wegovy. Going a step further, it supports more efficient fat loss by boosting the metabolic rate.

How Does Amycretin Work?

How Does Amycretin Work?

GLP-1 is an incretin hormone that’s released in the gastrointestinal tract in response to food. After its release, the blood carries it to the brain, where it binds with GLP-1 receptors, promoting satiety and loss of appetite.

When people take Amycretin, the semaglutide it provides serves the same function, bypassing the need for a full stomach.

Working on a second level, the drug slows gastric emptying. This forces food to remain in the stomach for longer than normal to prolong satiety.

The semaglutide in the pills aids insulin secretion, while also inhibiting glucagon secretion. By acting on the two hormones in the way that it does, semaglutide helps keep blood sugar levels on an even keel. It’s this ability that gives the drug such value as an anti-diabetic agent. It’s also an ability that may contribute to weight loss.

When blood sugar levels fluctuate, they may drop too low. The brain reacts to this by initiating cravings for sugar and carbs. Semaglutide can prevent this from happening, sparing its users from having to endure unpleasant battles with cravings.

As already stated, Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA). There are other drugs in this class but none of them has been proven to be safe or effective.

DACRAs are currently being evaluated as potential treatments for obesity and weight-related metabolic disorders. They target both the amylin and calcitonin hormone receptors.

Amylin is a pancreas hormone that may support weight loss by suppressing glucagon secretion and slowing gastric emptying.

Calcitonin is a hormone that plays a role in calcium and bone metabolism. Research suggests calcitonin receptor activation may result in faster metabolism.

Related Content: Strong Over the Counter Appetite Suppressants

Who Will Be Able to Use Amycretin Weight Loss Pills?

If Amycretin gains FDA approval for use in the role of weight management, there may be many people who are keen to obtain it but not able to. Several factors can influence the decision to provide prescription weight loss medications.

Firstly, it’s necessary to have a positive attitude and a strong commitment to losing weight. People who cannot prove they have been making appropriate efforts with diet and exercise may not be able to obtain a supply of Amycretin

Body mass index (BMI) can also be a deal breaker. The FDA only permits doctors to prescribe approved weight loss medications to people who have a BMI of 30 or higher. People with this BMI are classed as obese. In some cases, doctors may be able to prescribe approved weight loss medications to people whose BMI is 27 or higher but only if they have a weight-related comorbidity such as high blood pressure or diabetes.

Strangely, when doctors prescribe medicines off-label, they do not have to stick to these guidelines. So, when a doctor is unable to prescribe approved weight loss options, such as Wegovy, they may consider prescribing off-label alternatives, such as Ozempic, instead.

If Amycretin gets FDA approval, it will be for weight loss because that is the medication’s primary intent. This will make it one of the harder options to obtain via a doctor.

Other factors will influence eligibility for an Amycretin prescription as well. Even people who have a high BMI may not be able to obtain it if they are using medications that may clash with the new medication or have health issues that might make using it unwise.

Amycretin Side Effects and Safety Considerations

Novo says its research data suggests Amycretin is safe and well-tolerated. However, only 16 people received the experimental weight loss pills in the clinical trial. That’s not enough to provide a good insight into the benefits and risks. It’s only a good starting point that signals the need for more thorough investigation.

GLP-1 receptor agonists have many known side effects. Amycretin is unlikely to be an exception. It contains semaglutide, which often causes gastrointestinal side effects such as nausea and diarrhea. Fortunately, adverse reactions such as these tend to subside as the body becomes used to the presence of the drug.

On a graver note, animal-based studies suggest GLP-1 receptor agonists may have the potential to cause thyroid tumors and/or pancreatitis (inflammation of the pancreas gland). Because of this, the FDA insists this type of medication be distributed alongside a black box warning that highlights the potential risks.

The black box warning is the strongest warning distributed with pharmaceutical products. It indicates data from clinical trials has shown that the drug bearing the warning carries a significant risk of preventable, serious, or even life-threatening adverse effects.

Amycretin is also a dual amylin and calcitonin receptor agonist. Because drugs of this type are still experimental, there is not enough data to support a thorough evaluation of the risks they may present.

How Amycretin Compares to Existing Prescription Diet Pills

The indications so far suggest Amycretin has the potential to become one of the most successful weight loss medications of the century, but how well does it bear up in comparison with some of the other popular prescription weight management products?

Rybelsus vs Amycretin

Rybelsus has more in common with Amycretin than any of the other options. Both are semaglutide medications you take orally. They also come from the same company.

As with Ozempic, Rybelsus is often used as an off-label medicine for weight loss. So people who are unable to obtain Amycretin due to the FDA restrictions relating to BMI may have the opportunity to use Rybelsus as a weight loss pill instead.

However, Rybelsus is only a basic semaglutide pill. With Amycretin, the drug appears to have a powerful ally. Cagrilintide may only be an experimental drug but appears to have a notable synergy with its better-established older brother.

Phentermine vs Amycretin

Phentermine is a very popular appetite-supressing diet pill that’s been available via prescription since the 1950s. It’s an amphetamine-based medication that, though often an effective option, can present a risk of addiction and is strictly for short-term use only. The maximum Phentermine prescription period is just 12 weeks.

People who can get a Phentermine prescription are very overweight or obese. That means they will have long weight loss journeys ahead of them and Phentermine will only be able to support them part of the way.

Amycretin may have the potential to cause several problems but addiction is unlikely to be one of them, so it’s a better candidate than Phentermine for anyone who needs ongoing, long-term weight loss support.

Related content: Strongest Phentermine Alternatives Without Prescription

Orlistat vs Amycretin

Orlistat is one of the few prescription weight management drugs that doesn’t provide appetite suppression. It’s a fat blocker that can help people reduce their daily calorie intake by inhibiting the actions of the digestive enzyme that breaks down dietary fats.

When people use Orlistat, up to 30% of the fat they consume with their food is not processed. It passes through the body intact, resulting in greasier stools and, when not treated with respect, the possibility of extreme or explosive diarrhea.

Fat is 9 calories per gram, so Orlistat treatment can work well for weight loss. However, it may also cause people to become deficient in important fat-soluble nutrients (vitamins A, D, E, and K). Amycretin does not present this type of problem. Data suggests it’s also a more powerful option that may appeal to people who are willing to overlook some of the risks that are inherent with medications that mimic GLP-1.

How Long Before Amycretin Becomes Available?

Novo Nordisk is planning to commence larger Phase II trials in the second half of 2024. Presuming things stay on track, the results should be available in early 2026 then, all being well, the company will be able to start evaluating Amycretin’s abilities more deeply via Phase III clinical trials.

This stage of a new drug’s development often lasts for 1-4 years. Presuming a positive outcome, once all the data is in, Novo will be able to submit it to the FDA and request it to consider approving Amycretin as a prescription weight management medication.

Only 25% to 30% of drugs that reach Phase III move on to the next stage so, although news of Novo’s new weight loss pill may have increased the company’s net worth, there is nothing to say it will eventually reach pharmacy shelves.

Even if it does, due to present research requirements and the need to pass through the FDA approval process, Amycretin weight loss pills are unlikely to be available for at least another 2-3 years.

Resources

Photo of author

About the author

Peter Williams has over 20 years of experience as an endocrinologist. Peter specializes in the study of diabetes, thyroid and parathyroid disorders, obesity, lipids disorders, and hormonal imbalances. He is actively involved in research investigating new medications and technologies for managing these chronic conditions.